6974-65-8

Upstream product

• 42174-01-6 methyl 2,4-dichlorocinnamate 
• 20595-45-3 2,4-dichlorocinnamic acid 
• 24653-94-9 2,3-dibromo-3-(2,4-dichloro-phenyl)-propionic acid 

Downstream Products

• 1616398-60-7 6-(2,4-dichlorophenyl)-2-phenylpyrimidin-4(3H)-one 
• 1616398-66-3 6-(2,4-dichlorophenyl)-2-(pyridin-4-yl)pyrimidin-4(3H)-one 
• 1616398-62-9 2-cyclopropyl-6-(2,4-dichlorophenyl)pyrimidin-4(3H)-one 
• 1616398-64-1 2-(4-aminophenyl)-6-(2,4-dichlorophenyl)pyrimidin-4(3H)-one 
• 1417560-52-1 1-(2,4-dichlorophenyl)-2-phenylethane-1,2-dione 

Relevant academic research and scientific papers

Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives

A series of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activity. The results showed that the majority of the target compounds displayed potent activity against erythromycin-susceptible S. pyogenes, erythromycin-resistant S. pneumoniae A22072 expressing the mef gene and S. pneumoniae AB11 expressing the mef and erm genes. Besides, most of the target compounds exhibited moderate activity against erythromycin-susceptible S. aureus ATCC25923 and B. subtilis ATCC9372. In particular, compounds 11a, 11b, 11c, 11e, 11f and 11h were found to exert favorable antibacterial activity against erythromycin-susceptible S. pyogenes with the MIC values of 0.015–0.125 μg/mL. Furthermore, compounds 10e, 11a, 11b and 11c showed superior activity against erythromycin-resistant S. pneumoniae A22072 with the MIC values of 0.25–0.5 μg/mL. Additionally, compound 11c was the most effective against all the erythromycin-resistant S. pneumoniae strains (A22072, B1 and AB11), exhibiting 8-, 8- and 32-fold more potent activity than clarithromycin, respectively.

3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS

The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R1, R2 and R3 have significances given in a claim 1. In addition, said invention relates to drugs containing at least one type of inventive amid. Because of the antagonist activity of an MCH-receptor, the inventive drugs are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.

Base precursor for heat-developable photosensitive material

A base precursor for heat-developable photosensitive material is disclosed. The precursor is comprised of a compound represented by general formula (I) or (II): The substituents within the general formulae are defined within the specification. The use of this novel base precursor makes it possible to obtain a material which is very stable at normal temperatures and which smoothly decomposes under heating at 80° C. or higher in order to release a basic constituent.